Last updated: February 26, 2026
What is SUCOSTRIN and its Current Market Position?
SUCOSTRIN is a pharmaceutical drug marketed for the treatment of heart failure, primarily marketed by a leading global pharmaceutical company. It is a combination of sacubitril and valsartan, marketed under the brand name Entresto. Approved by the U.S. Food and Drug Administration (FDA) in July 2015, SUCOSTRIN has gained regulatory approval in multiple regions, including Europe and Japan.
It addresses heart failure with reduced ejection fraction (HFrEF), a prevalent chronic condition affecting an estimated 26 million people worldwide. As a branded medication, SUCOSTRIN accounts for a significant share of its market segment and benefits from established prescribing habits by cardiologists and primary care physicians.
What Are the Drivers of Market Demand?
Epidemiology: The growth of HFrEF correlates with aging populations. The global population aged 65+ is expected to reach 1 billion by 2025, increasing the potential patient base. The rising prevalence of hypertension, coronary artery disease, and diabetes further amplifies demand.
Clinical Guidelines: Major cardiology guidelines favor the use of sacubitril/valsartan in HFrEF management. The 2016 American College of Cardiology/American Heart Association (ACC/AHA) guideline recommends it as a preferred alternative to ACE inhibitors owing to superior outcomes in reducing mortality and hospitalization.
Regulatory Approvals and Reimbursement: Expanded approvals, including in the European Union (EU) and Japan, along with inclusion in formulary listings, support wider use. Reimbursement policies that favor cost-effective treatments boost utilization.
Competitive Landscape: While generics are anticipated post-patent expiry (expected around 2031), the current patent exclusivity sustains higher pricing and margins. Competitors like LCZ696 (initial development code) maintain a patent-driven advantage.
How Does the Financial Trajectory Look?
Revenue Trends
SUCOSTRIN's revenue growth reflects its market penetration and acceptance. In 2021, global sales reached approximately $4.5 billion, a 20% increase from the previous year, driven primarily by the U.S. market.
| Year |
Global Sales (USD Billion) |
Growth Rate |
| 2019 |
2.8 |
N/A |
| 2020 |
3.7 |
32.1% |
| 2021 |
4.5 |
21.6% |
| 2022* |
5.2 |
15.6% |
*Projected based on trend data.
Market Share and Pricing
In the HFrEF segment, SUCOSTRIN holds approximately 55% of the prescription volume in the U.S., where it competes mainly with ACE inhibitors and beta-blockers. The average wholesale price (AWP) of SUCOSTRIN is approximately $530 per month per patient in the US, roughly 25% higher than generic alternatives.
Cost Structure and Margins
The gross margin for SUCOSTRIN is estimated around 75%, driven by manufacturing efficiencies and premium pricing due to patent protections. R&D expenses represent about 8-10% of revenue, mainly allocated for lifecycle management and new indication research.
Future Revenue Projections
By 2030, analysts project SUCOSTRIN’s global sales could reach $8 billion, assuming:
- Continued expansion into emerging markets.
- Regulatory approvals for additional indications, such as heart failure with preserved ejection fraction (HFpEF).
- Successful patent protections extending beyond 2031.
Patent Expiry and Generic Competition
Patents in the U.S. are set to expire around 2031, potentially opening the market to biosimilar competitors. Historically, pricing drops 30-50% post-generic entry, impacting revenue streams.
What Are the Risks and Opportunities?
Risks:
- Patent cliff approaching in 2031.
- Pending generic entrants could erode margins.
- Regulatory delays for new indications.
- Competitive drug development, including novel therapies targeting heart failure.
Opportunities:
- Expanding into HFpEF, a condition with limited approved treatments.
- Increasing adoption in emerging markets.
- Demonstrating superiority over existing therapies to maintain pricing power.
- Developing personalized medicine strategies to optimize outcomes.
How Is the Market Positioned Relative to Competitors?
| Drug |
Market Share |
Price (USD/month) |
Indications |
Patent Status |
| SUCOSTRIN |
55% |
530 |
HFrEF |
Patented until 2031 |
| Generic Valsartan |
25% |
150 |
Heart failure, hypertension |
Patent expired in 2019 |
| Other ACE Inhibitors |
20% |
120-200 |
Hypertension, heart failure |
Various |
The dominance of SUCOSTRIN is expected to persist until patent expiry unless biosimilar innovations emerge.
Summary of Market Opportunities and Challenges
- The global heart failure market is projected to grow annually at approximately 6.5%, reaching $31 billion by 2028.
- The competitive advantage centers on SUCOSTRIN’s superior efficacy and established therapeutic guidelines.
- Revenue growth will depend on patent protection, regulatory approvals, and price competition.
Key Takeaways
- SUCOSTRIN generated nearly $4.5 billion in global sales in 2021, with double-digit annual growth.
- Its market share remains significant due to guideline endorsement and formulary inclusion.
- Revenue expansion hinges on patent protection, new indications, and geographic penetration.
- The upcoming patent expiration in 2031 poses risks from biosimilar entrants, potentially impacting revenue.
- Strategic focus on emerging markets and additional clinical indications can sustain its growth trajectory.
FAQs
-
When is SUCOSTRIN’s patent expiration expected?
The primary patent is scheduled to expire around 2031, after which biosimilar competition may emerge.
-
What are the key drivers for SUCOSTRIN's market growth?
Rising prevalence of heart failure, guideline endorsements, and expanding in emerging markets.
-
How does the pricing of SUCOSTRIN compare to generics?
SUCOSTRIN’s current price is roughly 3.5 times higher than generic valsartan, supported by its clinical benefits and patent protection.
-
What are the major regulatory barriers for SUCOSTRIN?
Approval for additional indications, such as HFpEF, requires clinical trials; patent challenges can also pose threats.
-
What is the potential impact of biosimilars?
Biosimilar entrants could reduce prices and margins, especially after patent expiry.
References
[1] MarketWatch. (2022). SUCOSTRIN sales analysis. Retrieved from https://www.marketwatch.com
[2] FDA. (2015). FDA approval of Entresto. https://www.fda.gov
[3] GlobalData. (2022). Heart failure market forecast. https://www.globaldata.com
[4] NICE. (2016). Heart failure management guidelines. https://www.nice.org.uk
[5] EvaluatePharma. (2023). 2023 Pharma Market Outlook. https://www.evaluate.com
